Biotech Values

[DewDiligence]

PPHM’s newest phase-2 HCV trial is an exercise in futility, IMO. It doesn’t measure SVR and the trial arms are not even blinded. That might be Ok if Bavituximab were a new drug, but PPHM has been touting Bavituximab as an “active agent” in HCV for several years with little or nothing to show in the way of hard data.

Management must think PPHM investors are the biggest suckers on the planet.